Indeed, the ABL1-inhibitor imatinib was used at a concentration of 5 μM that, as reported in the literature, represents the steady state plasma concentration after 5–7 days of treatment in adult CML at a dose of 400 mg/day (Druker et al., 2001), and is 20 times higher than the IC50 calculated in vitro on cellular tyrosine phosphorylation assay (Deininger et al., 2005). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.